The combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer

HUANG Shicong; et al

doi:10.13406/j.cnki.cyxb.2003.03.023

您当前的位置：

首页 >

文章列表页 >

The combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer

更新时间：2024-01-17

- The combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer
- Journal of Chongqing Medical University Issue 3, Pages: 331-333(2003)
- 作者机构：
  
  1. 重庆医科大学临床学院肺科
  2. 重庆医科大学临床学院肺科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2003.03.023
  CLC： R734.2
- Published：2003，
扫描看全文
[1]黄仕聪,吴亚梅.异环磷酰胺、长春酰胺和顺铂联合治疗晚期非小细胞肺癌[J].重庆医科大学学报,2003(03):331-333.

HUANG Shicong, et al. The combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer. [J]. Journal of Chongqing Medical University (3):331-333(2003)
[1]黄仕聪,吴亚梅.异环磷酰胺、长春酰胺和顺铂联合治疗晚期非小细胞肺癌[J].重庆医科大学学报,2003(03):331-333. DOI： 10.13406/j.cnki.cyxb.2003.03.023.

HUANG Shicong, et al. The combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer. [J]. Journal of Chongqing Medical University (3):331-333(2003) DOI： 10.13406/j.cnki.cyxb.2003.03.023.

摘要

目的 :评价异环磷酰胺（IFO）、长春酰胺（VDS）和顺铂（DDP）联合治疗晚期非小细胞肺癌（NSCLC）的疗效和毒性反应。方法 :5 2例晚期NSCLC给予IFO、VDS和DDP联合化疗

第 1～ 5天静脉滴注IFO 1.5～ 2 g/m2

美安（mesna） 4 0 0mg

在IFO后 0、4、8h静脉推注 ;第 1、8天静脉推注VDS 4mg ;第 1天静脉滴注DDP 6 0mg/m2 。 4周为一个周期

两个周期后评价疗效和毒性反应

随访生存期。结果 :IFO、VDS和DDP联合化疗总有效率为 4 4 .2 %

初治和复治病例有效率分别为 4 7.1%和38.9%

两组间差别无显著性（P >0 .0 5 ）。中位生存期为 8个月。毒性反应主要是骨髓抑制

表现为白细胞和血小板的减少较为明显

白细胞和血小板下降常出现于给药后第 8～ 12天。结论 :IFO、VDS和DDP联合治疗晚期NSCLC有较好的临床疗效

对复发病例也有较好疗效

毒性反应耐受性较好

如辅以G -CSF防治重度骨髓抑制

有较好的临床应用价值

Abstract

Objective:To evaluate the efficacy and toxicity of the combined chemotherapy of ifosfamide plus vindesine and cisplatin in advanced non-small cell lung cancer.Methods:Fifty-two patients with advanced non-small cell lung cancer were treated by the combined chemotherapy of ifosfamide plus vindesine and cisplatin for two cycles:ifosfamide 1.5～2.0g/m 2 iv drip on day 1～5

mesna 400mg iv at 0

8 hours after using ifosfamide;vindesine 4mg iv on day 1

8;cisplation 60mg/m 2 iv drip on day 1.The response

toxicity and survival period were evaluated.Results:The total response rate was 44.2%.The response rate of patients in primary treatment was 47.1% and that of return cases was 38.9% ( P >0.05).The median duration of survival was eight months.The major toxicity was the inhibition of bone marrow

especially of leukocyte and platelet.Leukopenia and thrombocytopenia often appeared at day 8～12.Conlusion:The combined chemotherapy of ifosfamide plus vindesine and cisplatin is effective in advanced non-small cell lung cancer including the returm cases

and the toxicity is tolerable.If G-CSF is used as a complementary therapy

this regimen could be quite clinically valuable.

关键词

非小细胞肺癌方案化疗

Keywords

non-small cell lung cancerRegimenchemotherapy

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative study of gemcitabine plus CBP and navelbine plus DDP regimen in the treatment of old patients with age NSCLC

Advances in immunotherapy in EGFR-mutated non-small cell lung cancer

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Effect of progressive muscle relaxation training on coping style and emotion of patients with lung cancer

Tebivudine as pre-emptive treatment against hepatitis B virus reactivation in patients after chemotherapy

Related Author

JIANG Youfan

et al

兰箭

Wei Kunchen

Wu Junfeng

Tang Hao

Xu Qiao

Jiang Yu

Related Institution

重庆医科大学附属第二医院呼吸科

Department of Respiratory Disease,the Second Affiliated Hospital,Chongqing Medical University

Beijing Garrison District Haidian 40th Separation Cadre Retreat

Department of Respiratory and Critical Care Medicine,Shanghai Changzheng Hospital

Department of Urology，The First Affiliated Hospital of Chongqing Medical University

⁰